抗TNFα治疗性纳米抗体®化合物奥佐利单抗的结构设计，以支持其强效且持久的临床疗效。 - Suppr

Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.

作者信息

Mima Masashi, Mishima-Tsumagari Chiemi, Nakano Koichiro, Morimoto Mai, Ogata Hitoshi, Sakata Mayumi, Iwaoka Ryo, Iwata Katsuya, Hachiuma Kenji, Iwamoto Kunihiko, Fujii Yasuyuki, Kurokawa Tomofumi

机构信息

Taisho Pharmaceutical Co., Ltd., 1-403, Yoshino-cho, Kita-ku, Saitama, 331-9530, Japan.

出版信息

Biochem Biophys Res Commun. 2024 Nov 19;734:150454. doi: 10.1016/j.bbrc.2024.150454. Epub 2024 Jul 26.

DOI:10.1016/j.bbrc.2024.150454

PMID:39083975

Abstract

摘要

相似文献

Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.抗TNFα治疗性纳米抗体®化合物奥佐利单抗的结构设计，以支持其强效且持久的临床疗效。

Biochem Biophys Res Commun. 2024 Nov 19;734:150454. doi: 10.1016/j.bbrc.2024.150454. Epub 2024 Jul 26.

[Pharmacological profiles and clinical efficacy of ozoralizumab (Nanozora 30 ‍mg Syringes for S.C. Injection), the first Nanobody compound in Japan].[日本首个纳米抗体化合物奥佐利珠单抗（用于皮下注射的30毫克纳米佐拉注射器）的药理特性及临床疗效]

Nihon Yakurigaku Zasshi. 2023;158(6):490-499. doi: 10.1254/fpj.23051.

Ozoralizumab, a Humanized Anti-TNFα NANOBODY Compound, Exhibits Efficacy Not Only at the Onset of Arthritis in a Human TNF Transgenic Mouse but Also During Secondary Failure of Administration of an Anti-TNFα IgG.奥扎鲁单抗，一种人源化抗 TNFα NANOBODY 化合物，不仅在人 TNF 转基因小鼠关节炎发病时表现出疗效，而且在抗 TNFα IgG 二次治疗失败时也表现出疗效。

Front Immunol. 2022 Feb 22;13:853008. doi: 10.3389/fimmu.2022.853008. eCollection 2022.

Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation.奥扎鲁单抗的独特结构是一种三价抗 TNFα 的纳米体药物复合物，具有减轻免疫复合物引起的炎症风险的潜在优势。

Front Immunol. 2023 Apr 14;14:1149874. doi: 10.3389/fimmu.2023.1149874. eCollection 2023.

Efficacy and pharmacokinetics of ozoralizumab, an anti-TNFα NANOBODY compound, in patients with rheumatoid arthritis: 52-week results from the OHZORA and NATSUZORA trials.奥扎鲁单抗，一种抗 TNFα NANOBODY 化合物，在类风湿关节炎患者中的疗效和药代动力学：OHZORA 和 NATSUZORA 试验的 52 周结果。

Arthritis Res Ther. 2023 Apr 13;25(1):60. doi: 10.1186/s13075-023-03036-4.

Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis.奥扎鲁单抗：首个用于类风湿关节炎的纳米抗体治疗药物。

Expert Opin Biol Ther. 2023 Jul-Dec;23(7):579-587. doi: 10.1080/14712598.2023.2231344. Epub 2023 Jul 11.

Efficacy and safety of anti-TNF multivalent NANOBODY® compound 'ozoralizumab' without methotrexate co-administration in patients with active rheumatoid arthritis: A 52-week result of phase III, randomised, open-label trial (NATSUZORA trial).抗 TNF 多价纳米体化合物“奥扎鲁单抗”在未联合甲氨蝶呤治疗活动期类风湿关节炎患者中的疗效和安全性：III 期、随机、开放标签试验（NATSUZORA 试验）的 52 周结果。

Mod Rheumatol. 2023 Aug 25;33(5):875-882. doi: 10.1093/mr/roac126.

Efficacy and safety of the anti-TNF multivalent NANOBODY® compound ozoralizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: A 52-week result of a Phase II/III study (OHZORA trial).抗 TNF 多价 NANOBODY ® 化合物奥佐拉珠单抗治疗甲氨蝶呤应答不足的类风湿关节炎患者的疗效和安全性：一项 II/III 期研究（OHZORA 试验）的 52 周结果。

Mod Rheumatol. 2023 Aug 25;33(5):883-890. doi: 10.1093/mr/roac119.

Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab.新一代抗TNFα药物：奥佐利单抗的实例

BioDrugs. 2024 May;38(3):341-351. doi: 10.1007/s40259-024-00648-3. Epub 2024 Apr 8.

Ozoralizumab: First Approval.奥佐利珠单抗：首次获批。

Drugs. 2023 Jan;83(1):87-92. doi: 10.1007/s40265-022-01821-0.

引用本文的文献

Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases.开发用于肿瘤坏死因子α（TNFα）介导疾病治疗应用的强效人源化TNFα抑制纳米抗体。

MAbs. 2025 Dec;17(1):2498164. doi: 10.1080/19420862.2025.2498164. Epub 2025 May 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献